Treatment | IC50a | DCFDA | GSH | TrxR | Annexin V(+) | JC-1 | BrdU |
---|---|---|---|---|---|---|---|
μM | geometric mean | % control | μmol · min−1 · ml−1 | % total | geometric mean | % total | |
Control | 23.7 ± 3.1 | 100 ± 0 | 2.24 ± 0.1 | 4.3 ± 0.2 | 132.5 ± 11.5 | 33.2 ± 1.8 | |
P-A | 37 ± 1.6 | 43.2 | 48.8 | 1.33 | 21.8 | 183 | 1.2 |
P-S | 98 ± 3.7 | 198.5 | 38.7 | 1.18 | 44.6 | 717 | 1.3 |
P-F | 65 ± 4.3 | 170.8 | 45.9 | 1.42 | 89.9 | 1295 | 6.0 |
P-I | 79 ± 2.9 | 88.1 | 46.5 | 2.04 | 67.3 | 235 | 12.7 |
Mean ± S.E.M. | 125.2 ± 36.0b | 45.0 ± 2.2*** | 1.5 ± 0.2* | 55.9 ± 14.7* | 607.5 ± 258.8* | 5.3 ± 2.7*** | |
5-FU | 173 ± 14.2 | 23.01 | 92.4 | 2.54 | 4.9 | 145.5 | 28.5 |
Oxaliplatin | 61 ± 5.9 | 21.6 | 92.8 | 2.24 | 5.2 | 163 | 19.9 |
Irinotecan | 167 ± 12.0 | 33 | 93.9 | 2.78 | 12.1 | 217 | 29.1 |
Chlorambucil | 135 ± 14.9 | 23.4 | 87.6 | 2.35 | 8.1 | 160 | 15.6 |
Vincristine | 55 ± 7.4 | 65.6 | 86.4 | 1.88 | 7.7 | 251 | 14.2 |
Mean ± S.E.M. | 33.3 ± 8.3 | 90.6 ± 1.5** | 2.4 ± 0.15 | 7.6 ± 1.3c | 187.3 ± 20.1* | 21.5 ± 3.2* |
a n ≥ three different experiments, each done in triplicate.
b Compared with control: P = 0.06.
c Compared with control: P = 0.063.
* P < 0.05;
** P < 0.01;
*** P < 0.001 compared with control.